Immunogenicity of a Monovalent Pandemic Influenza A H1N1 Virus Vaccine with or without Prior Seasonal Influenza Vaccine Administration | Zendy

Hidetoshi Igari | Zendy; Akira Watanabe | Zendy; Shunsuke Segawa | Zendy; Akiko Suzuki | Zendy; Mariko Watanabe | Zendy; Takayuki Sakurai | Zendy; Masaharu Watanabe | Zendy; Koichiro Tatsumi | Zendy; Mikio Nakayama | Zendy; Kazuo Suzuki | Zendy; Takeyuki Sato | Zendy

Open Access

Immunogenicity of a Monovalent Pandemic Influenza A H1N1 Virus Vaccine with or without Prior Seasonal Influenza Vaccine Administration

Author(s) -

Hidetoshi Igari,

Akira Watanabe,

Shunsuke Segawa,

Akiko Suzuki,

Mariko Watanabe,

Takayuki Sakurai,

Masaharu Watanabe,

Koichiro Tatsumi,

Mikio Nakayama,

Kazuo Suzuki,

Takeyuki Sato

Publication year - 2012

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00077-12

Subject(s) - immunogenicity , titer , virology , medicine , pandemic , hemagglutination assay , live attenuated influenza vaccine , influenza vaccine , virus , antibody titer , antibody , vaccination , immunology , covid-19 , disease , infectious disease (medical specialty)

The immunogenicity of pandemic influenza A H1N1 virus (A/H1pdm) vaccine might be modified by prior seasonal trivalent influenza vaccine (sTIV) administration. We conducted a retrospective analysis of immunogenicity of 243 health care workers (number of sTIV-positive [sTIV + ] subjects, 216; number of sTIV − subjects, 27) by hemagglutination inhibition. There was no significant difference in the ratios of antibody titers of ≥40 (41.2% versus 48.1%; P = 0.49) and fold increases in geometric mean titer (3.8 versus 4.5; P = 0.37). sTIV injected 7 to 10 days prior to A/H1pdm vaccine administration did not interfere with the immunogenicity of the latter.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research